Prevalence and Incidence of Neuromyelitis Optica Spectrum Disorder in Korea: Population Based Study

Hye Lim Lee,1 Jae Young Kim,2 Jin Myoung Seok,3 Yoon-Ho Hong,4 Nam Gu Lim,5 Ha Young Shin,6 Byung-Jo Kim,7 Soon-Young Hwang,7 Ju-Hong Min,8,9 and Byoung Joon Kim8,9

1Department of Neurology, Korea University College of Medicine, Seoul, Korea
2Department of Digital Healthcare, Samsung Advanced Institute for Health Sciences & Technology, Seoul, Korea
3Department of Neurology, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea
4Department of Neurology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea
5Department of Medical Administration and Information, Daejeon Health Institute of Technology, Daejeon, Korea
6Department of Neurology, Yonsei University College of Medicine, Seoul, Korea
7Department of Biostatistics, Korea University College of Medicine, Seoul, Korea
8Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
9Neuroscience Center, Samsung Medical Center, Seoul, Korea

ABSTRACT

Background: Although neuromyelitis optica spectrum disorder (NMOSD) is known to be a rare disease, its prevalence and incidence have not yet been studied in Korea. We performed a population-based study to examine the prevalence and incidence of NMOSD in Korea using data from the Korean National Health Insurance (NIH) claims database.

Methods: Data from 2013 to 2017 were obtained, with a washout period set as 2013 and 2014. The prevalence and incidence of NMOSD in 2016 and 2017 were calculated using population census data. Subjects were divided into 5 groups at 15-year intervals, depending on the age at which the diagnostic code was entered. The relative risk (RR) for each age group was compared with the oldest (≥ 60 years) age group.

Results: The overall prevalence was estimated to be 3.36 and 3.56 per 100,000 individuals, with an incidence of 0.41 and 0.65 per 100,000 individuals-year in 2016 and 2017, respectively. The mean age was 43.08 (standard deviation, 14.56) years, and the ratio of male to females was 1:4.7. The incidence was higher in female individuals aged between 30 and 59 years (RR, 2.8–3.05; P < 0.05).

Conclusion: Nationwide prevalence of NMOSD in Korea was 3.36 and 3.56/100,000 and its incidence was 0.41 and 0.65/100,000-year in 2016 and 2017 respectively.

Keywords: Neuromyelitis Optica Spectrum Disorder; NMOSD; Prevalence; Incidence
INTRODUCTION

Neuromyelitis optica spectrum disorder (NMOSD) is a type of demyelinating disorder of the central nervous system (CNS) characterized by optic neuritis, transverse myelitis, or both. Approximately 75%–90% of patients with NMOSD have antibodies against aquaporin-4 (AQP4 Ab), a type of water channel, which is believed to be pathognomonic.\textsuperscript{1} In general, NMOSD is considered to be a rare inflammatory CNS disease. There have been a few epidemiological studies that have investigated NMOSD worldwide.\textsuperscript{2-7} Several studies have estimated the prevalence of NMOSD in Caucasians, with variations among the studies. The prevalence of NMOSD was reported to be 1.96 per 100,000 persons in Southeast Wales, 0.52 per 100,000 persons in Cuba, and 4.44 per 100,000 persons in Denmark.\textsuperscript{8,9} However, there may be differences in the prevalence in Asians due to racial differences.\textsuperscript{10} In a recent study from New Zealand and Australia, NMOSD was reported to be approximately three times more common in Asians than in other ethnicities (1.57 vs. 0.57 per 100,000 persons).\textsuperscript{11}

Korean studies investigating the prevalence and incidence of NMOSD have not been conducted. Therefore, we investigated the prevalence and incidence of NMOSD in Korea using data from the National Health Insurance (NHI) claims database between 2014 and 2017. Because the NHI database reflects the nationwide real-world medical record, it is very helpful in determining the national prevalence and incidence of certain diseases in Korea. Additionally, we evaluated the relative risk (RR) for age by sex and compared these results with an older age group.

METHODS

Data from the NHI and Health Insurance Review and Assessment Service (HIRA)
The Korea has a mandatory public medical insurance program known as the “NHI,” and each hospital provides patient medical usage lists to the HIRA, which is one of the central government organizations linked to the NHI. HIRA assesses the appropriateness of medical fees and the adequacy of medical services through a medical claims review of each hospital. The patients can select their desired hospital from a range of primary care clinics to tertiary hospitals. The hospital provides an individual medical record to NHI. NHI collects data for each patient, including demographic information, the diagnosis which is represented by a diagnostic code entered by the physician, drug management, and procedures performed by public health in Korea. Therefore, the NHI claims database can provide representative, nationwide healthcare information on specific diagnoses and track patients longitudinally over multiple years.

Identification of NMOSD
Data from the NHI claims database, from 2014 to 2017, were used to select patients with NMOSD. Patients with NMOSD of any age who appeared in the databases between January 2014 and December 2017 were identified and selected. More specifically, patients with NMOSD were defined as those with a primary or secondary diagnostic code of G36.0 according to the Korean Standard Classification of Disease 2015, which is the Korean version of the International Classification of Diseases, 10th Revision, in the departments of neurology, ophthalmology, and pediatrics.

To improve the accuracy of the diagnosis, we combined data regarding prescriptions for immunosuppressants, except oral steroids, after the registration of the NMOSD diagnosis.
Data from 2014 to 2017 were obtained. However, the washout period was set from 2014 to 2015 to survey an accurate incidence rate. The incident case was defined as the first entry of the diagnostic code G36.0 (de novo) on admission or from the outpatient medical records for 2016 and 2017, that is, the people who had no previous history of the diagnostic code G36.0.

**Population data**

Population data for Korea for 2016–2017 were obtained from the Korean Statistical Information Service (http://kosis.kr/). The total population in Korea in 2016 and 2017 was approximately 50 million. The population was stratified according to sex and grouped into 15-year age intervals. The prevalence and incidence of NMOSD were calculated based on these data.

**Estimation of prevalence and incidence**

Prevalence is defined as the total number of cases of a disease existing in a specified population at a designated time. The prevalence rate is the total number of cases of a disease existing in a population divided by the total population. Incidence is defined as the number of newly diagnosed cases of a given disease during a given period in a specified population. The crude prevalence for each year (2016 and 2017) was calculated, and patients with NMOSD were analyzed according to sex and age at which the diagnostic code of NMOSD was entered. Furthermore, the annual crude incidences in 2016 and 2017 were calculated. The washout period was set from 2014 to 2015. Incident case was defined as the first entry of the diagnostic code NMOSD in the medical records in 2016 and 2017. Finally, standardized incidence and prevalence rates, adjusted for sex and age, were calculated using population census data for 2016 and 2017, which were obtained from the Korean Statistical Information Service in the Korea National Statistical Office. Depending on the age at which the diagnostic code was entered, the included patients were divided into 5 groups according to the following intervals: <15; 15–29; 30–44; 45–59; and ≥60 years.

The prescribed immunosuppressive agents were described from the NHI database. We analyzed the prescribed data of the immunosuppressive agents, which included azathioprine, cyclosporine, mycofenolate mofetil, rituximab, methotrexate, and mitoxantrone. Oral steroids were not included.

**Statistical analysis**

The χ² test was used to compare the prevalence and incidence according to sex and the diagnostic code entered age group. The RR of each age group was assessed and compared with the older (≥60 years) group. The group under 15 years of age was not included in the RR statistical analysis because of the small number of patients in this group. Data with 95% confidence intervals (CIs) that did not contain 1 in RR and differences with a P value < 0.05 were considered statistically significant in all analyses. All statistical analyses were performed using SAS Enterprise Guide 7.1 (SAS Institute Inc., Cary, NC, USA) and SPSS version 20.0 (IBM Corporation, Armonk, NY, USA).

**Data availability statement**

Data can be shared on request by directly contacting the corresponding author.

**Ethics statement**

This study was approved by the Institutional Review Board (IRB) of Korea University Guro Hospital (IRB No. 2017GR0166). Given the retrospective nature of the study and the use of anonymized patient data, the requirement for informed consent was waived.
RESULTS

Prevalence and incidence

A total of 2,390 NMOSD cases in 2016 and 2,410 cases in 2017 were identified according to the diagnostic code (G36.0). Data for 2014 and 2015 were excluded for accuracy to identify incident cases. Patients with a documented prescription for immunosuppressants, except oral steroids, and who had a diagnosis of NMOSD were selected. Ultimately, data of 1,676 cases in 2016 and 1,776 in 2017 were extracted and used to calculate the prevalence of NMOSD in Korea.

The prevalence and incidence rates for NMOSD in Korea for 2016 and 2017 were calculated. In 2016, the overall prevalence rate was 3.36 per 100,000 persons, and the incidence rate was 0.65 per 100,000 person-years. In 2017, the overall prevalence rate was 3.56 per 100,000 persons, and the incidence rate was 0.41 per 100,000 person-years. The data from 2016 and 2017 were analyzed according to age and sex considering the recent criteria revision for diagnosing NMOSD. Prevalence and incidence rates according to age and sex are summarized in Table 1. The prevalence and incidence of NMOSD were higher in female individuals than in male individuals (male:female ratio, 1:4.69 in incident cases; 1:4.11 in prevalent cases). In prevalent cases for 2017, the mean ages were 43.7 (standard deviation [SD], 14.3) years for the male group and 43.1 (SD, 14.1) years for the female group, and there was no significant difference relating to sex ($P = 0.53$). Age-specific prevalences in 2017 are shown in Fig. 1. The prevalence and incidence rates in individuals aged between 30 and 59 years when the diagnostic code was entered were higher than the overall prevalence and incidence rates.

Table 1. Prevalence and incidence of NMOSD in Korea in 2016 and 2017

| Age, yr | Prevalence (per 100,000 population) | Incidence (per 100,000 population-year) |
|--------|-------------------------------------|----------------------------------------|
|        | 2016 | 2017 | 2016 | 2017 | 2016 | 2017 | 2016 | 2017 |
|        | Subtotal | Male | Female | Subtotal | Male | Female | Subtotal | Male | Female |
| < 15   | 0.44 | 0.17 | 0.73 | 0.48 | 0.15 | 0.84 | 0.10 | 0.06 | 0.15 |
| 15–29  | 3.07 | 1.14 | 5.23 | 3.12 | 1.09 | 5.39 | 0.51 | 0.26 | 0.79 |
| 30–44  | 4.89 | 2.11 | 7.79 | 5.41 | 2.32 | 8.63 | 0.77 | 0.26 | 1.30 |
| 45–59  | 4.75 | 1.55 | 7.97 | 5.04 | 1.65 | 8.68 | 1.08 | 0.46 | 1.70 |
| > 60   | 2.01 | 1.12 | 2.69 | 2.01 | 1.12 | 2.67 | 0.48 | 0.27 | 0.74 |
| Overall| 3.36 | 1.33 | 5.38 | 3.56 | 1.39 | 5.71 | 0.65 | 0.28 | 1.01 |

NMOSD = neuromyelitis optica spectrum disorder.

*Age means the age at which the diagnostic code for NMOSD was entered.

Fig. 1. Age-specific prevalence in Korea in 2017. The prevalence in individuals aged between 30 and 59 years was higher than the overall prevalence.
Additionally, they were extremely low in individuals aged < 15 years. Both male and female individuals exhibited similar tendencies. However, these tendencies were more pronounced in female individuals.

**Treatment state of immunosuppressive agents**

We analyzed the prescription status of immunosuppressive agents from claim data in 2017. The most commonly used drugs were azathioprine (38%) and mycophenolate mofetil (19%). Nine percent of the extracted patients were treated with rituximab, and about 5% of the patients were prescribed other immunosuppressants such as tacrolimus, mitoxantrone, and methotrexate.

**RR compared with the older diagnostic code entered age group**

The incidence of NMOSD was higher in female individuals aged between 30 and 59 years than in female individuals in the older diagnostic code entered age group (≥ 60 years): RR, 2.82 (95% CI, 1.70–4.69) for those aged 30–44 years; RR, 3.05 (95% CI, 1.86–4.99) for those aged 45–59 years. However, such differences were not found among the male diagnostic code entered age groups (Table 2 and Fig. 2).

**DISCUSSION**

This population-based study was the first to investigate the prevalence and incidence of NMOSD in Korea using data from the NHI database. We estimated the prevalence of NMOSD to be 3.36 and 3.56 per 100,000 persons and the incidence of NMOSD to be 0.41 and 0.65 per 100,000 person-years in 2016 and 2017, respectively.

### Table 2. NMOSD incidence in younger age groups compared with older age group in 2017

| Age, yr | RR (95% CI) | P value | RR (95% CI) | P value | RR (95% CI) | P value |
|---------|-------------|---------|-------------|---------|-------------|---------|
| 15–29   | 0.84 (0.30–2.31) | 0.73 | 1.19 (0.63–2.23) | 0.60 | 1.00 (0.59–1.71) | 1.00 |
| 30–44   | 1.68 (0.72–3.93) | 0.22 | 2.82 (1.70–4.69) | <0.001 | 2.32 (1.50–3.58) | <0.001 |
| 45–59   | 1.78 (0.78–4.07) | 0.16 | 3.05 (1.86–4.99) | <0.001 | 2.51 (1.65–3.83) | <0.001 |

NMOSD = neuromyelitis optica spectrum disorder, RR = relative risk, CI = confidence interval.

*Age means the age at which the diagnostic code for NMOSD was entered.*
The prevalence reported in the current study was higher than that reported in previous studies from New Zealand and Australia in Asian individuals (prevalence, 1.50 per 100,000 persons), Southeast Wales (United Kingdom) (prevalence, 2 per 100,000 persons), and Isfahan, Iran (1.9 per 100,000 population). However, the prevalence was consistent with that reported in recent studies from the United States, India, and Cuba. Although these differences were concordant with ethnic variations, these estimates were lower than those published in several previous population-based studies for Caucasian or Afro-Caribbean individuals (prevalence, 4.4 per 100,000 incidence; 0.4 per 100,000). Additionally, this prevalence was higher than that in a study from southern Japan (1.64 per 100,000) and equivalent to the prevalence of NMOSD in northern Japan (4.1 per 100,000). Our incidence was consistent with that reported in previous results from other countries with similar prevalence rates. This result should be confirmed in further follow-up studies, considering that the diagnostic criteria for NMOSD has recently been revised. The results of several studies to date regarding the worldwide prevalence and incidence of NMOSD are summarized in Table 3.

The prevalence of multiple sclerosis (MS) was estimated to be 3.5 per 100,000 individuals in a previous study from Korea. In the United States, the prevalence of NMOSD is estimated to be approximately 1%–2% of that of MS. These data are not concordant with the results of the present study. However, it is important to consider racial differences. According to the results of a recent study, non-white patients with NMOSD tended to have a younger onset, more likelihood of a cerebral syndrome, and more severe disability than white patients. These racial differences may be influenced by the ratio of NMOSD to MS in Korea. Additionally, it is important to be aware that the previous Korean study was not only based on data from 2000 to 2005 and verified cases from major referral hospitals, but the differential diagnosis of NMOSD was unclear at that time owing to uncertainties with testing for AQP4 antibodies. Therefore, it was estimated that the prevalence was calculated without a clear distinction between MS and other demyelinating diseases such as NMOSD. A further follow-up study on MS may be needed to more clearly establish the ratio of MS and NMOSD in Korea. In recent published study, the prevalence of NMOSD patient was estimated 2.56 in 2016. We included the patients enrolled in secondary diagnosis, which may be overestimated, although we have used the history of drug. However, other study also may have been underestimated because they excluded people who once visited the clinic with NMOSD.

Table 3. Prevalence and incidence studies investigating neuromyelitis optica spectrum disorder

| Reference | Region/country | Crude prevalence (95% CI/100,000) | Crude incidence (95% CI/100,000) |
|-----------|----------------|----------------------------------|----------------------------------|
| 2         | Cuba           | 0.52 (0.39–0.68)                 | 0.053 (0.04–0.068)              |
| 3, 19     | North America  | 2.3 (0.6–3.9) in Martinique      | 0.19 (0.15–0.23)                |
|           | Martinique & Guadeloupe | 2.9 (1.1–4.7) in Guadeloupe    |                                  |
| 4         | United Kingdom | 0.72                             | 0.08 (0.03–0.16)                |
| 5         | United States  | 3.9                              | 0.7                              |
| 7         | Malaysia       | 1.99 (1.09–3.35)                 | -                                |
| 8         | Wales South East | 1.96 (1.22–2.97)                  | -                                |
| 9         | Denmark        | 4.4 (3.1–5.7)                    | 0.4 (0.3–0.54)                  |
| 13        | India          | 2.6                              | -                                |
| 14        | Iran           | 1.9 (1.6–2.3)                    | -                                |
| 17        | Japan          | 4.1 (2.2–6.9)                    | -                                |

CI = confidence interval.
In this study, higher prevalence and incidence were observed in individuals aged between 30 and 59 years when the diagnostic code was entered than in those aged > 60 years. NMOSD was extremely rare in individuals aged < 15 years. The rarity of childhood incidence of NMOSD was also observed in previous studies on the incidence of CNS demyelinating diseases in a multiethnic cohort of children. Our incidence result was reasonable in the group aged < 15 years when the diagnostic was entered. In the sub-analysis according to age, the incidence rates were higher in female individuals aged between 30 and 59 years than in those from the older age group (RR, 2.82 [95% CI, 1.94–4.34] for those aged 30–44 years; RR, 3.05 [95% CI, 1.84–4.17] for those aged 45–59 years). This was not observed in male individuals. These differences may be because of the effects of female hormones. We evaluated the risk of incidence in the groups of fertile female individuals compared with non-fertile postmenopausal elderly patients. Although the fertile women groups showed a higher risk of incidence, there was a possibility of other causes, besides female hormone exposure, considering the mean age of menarche was 12.7 years and that menopause developed at 49.3 years of age in Korean.

About 60% of NMOSD patients used azathioprine and mycophenolate mofetil, although there are overlapping patients owing to drug changes. According to the medical fee standard of HIRA in Korea, patients could be treated with secondary line therapy such as rituximab in refractory cases for first-line therapy. Therefore, most patients had no choice but to use azathioprine or mycofenolate mofetil. The efficacy of both drugs was not different in NMOSD.

Our study had several limitations owing to the use of the NHI claims data. First, it was possible that the primary or secondary diagnosis of NMOSD was miscoded (i.e., other than G36.0). We could not access any clinical information, including the results of laboratory tests, such as that for the AQP4 antibody, or imaging studies such as magnetic resonance imaging. Therefore, we used a prescription for immunosuppressant(s) as an additional inclusion criterion to increase the validity of NMOSD diagnosis. Nevertheless, we may have underestimated the prevalence and incidence of NMOSD. In our study, NMOSD patients without a drug prescription may have been excluded because of our operational definition considering the use of immunosuppressant prescriptions except for oral steroid agents. However, approximately 96%–98% of patients with NMOSD were treated with immunosuppressive agents in a recent study involving several ethnicities. Third, the incidence may have been overestimated owing to revisions of the NMOSD criteria in 2015. However, we have found it more beneficial to use up-to-date data to identify recent trends in the prevalence and incidence of NMOSD in Korea. Furthermore, because the government has recently expanded coverage for NMOSD patients in Korea, there is a risk that the prevalence and incidence will be overestimated. Further follow-up longitudinal studies are needed to overcome these limitations. Finally, data from the NHI claims database do not specify the age at onset, but rather the age at diagnosis and do not include mortality-related information. However, the NHI claims database has merits in that it completely covers the entire population of Korea despite the limitations mentioned above.

This study was the first population-based investigation of the prevalence and incidence of NMOSD in the Korea using data from the NHI claims database. Nationwide prevalence of NMOSD in Korea was 3.36 and 3.56/100,000 and its incidence was 0.41 and 0.65/100,000-year in 2016 and 2017 respectively. We demonstrated that NMOSD is a rare disease in Korea and hope to perform further studies, including other epidemiologic features, in the future.
REFERENCES

1. Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. *JAMA Neurol* 2014;71(3):276-83.

2. Cabre P. Environmental changes and epidemiology of multiple sclerosis in the French West Indies. *J Neurol Sci* 2009;286(1-2):58-61.

3. Cabrera-Gómez JA, Kurtzke JF, González-Quevedo A, Lara-Rodriguez R. An epidemiological study of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom. *J Neurol* 2009;256(1):35-44.

4. Jacob A, Panicker J, Lythgoe D, Elsone L, Mutch K, Wilson M, et al. The epidemiology of neuromyelitis optica spectrum disease in adults in the United Kingdom. *J Neurol Sci* 2013;324(1-2):96-101.

5. Flanagan EP, Cabre P, Weinshenker BG, Sauver JS, Jacobson DJ, Majed M, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum disease. *Ann Neurol* 2016;79(5):775-83.

6. Ashtari F, Safaei A, Shayannejad V, Najafi MA, Vesal S. Neuromyelitis optica spectrum disease characteristics in Isfahan, Iran: a cross-sectional study. *J Res Med Sci* 2017;22:11101.

7. Hor JY, Lim TT, Chia YK, Ching YM, Cheah CF, Tan K, et al. Prevalence of neuromyelitis optica spectrum disorder in the multi-ethnic Penang Island, Malaysia, and a review of worldwide prevalence. *Mult Scler Relat Disord* 2018;19:20-4.

8. Cossburn M, Tackley G, Baker K, Ingram G, Burtonwood M, Malik G, et al. The prevalence of neuromyelitis optica in South East Wales. *Eur J Neurol* 2012;19(4):655-6.

9. Asgari N. Epidemiological, clinical and immunological aspects of neuromyelitis optica (NMO). *Dan Med J* 2013;60(10):B4730.

10. Kim SH, Mealy MA, Levy M, Schmidt F, Ruprechtsk K, Paul F, et al. Racial differences in neuromyelitis optica spectrum disorder. *Neurology* 2018;91(22):e2089-99.

11. Bukhari W, Prain KM, Waters P, Woodhall M, O’Gorman CM, Clarke L, et al. Incidence and prevalence of NMOSD in Australia and New Zealand. *J Neurol Neurosurg Psychiatry* 2017;88(8):632-8.

12. Pandit L, Asgari N, Apiwattanakul M, Palace J, Paul F, Leite MI, et al. Demographic and clinical features of neuromyelitis optica: a review. *Mult Scler* 2015;21(7):845-53.

13. Etemadifar M, Dashti M, Vosoughi R, Abtahi SH, Ramagopalan SV, Nasr Z. An epidemiological study of neuromyelitis optica in Isfahan. *Mult Scler* 2014;20(14):1920-2.

14. Matrie RA, Gryba C. The incidence and prevalence of neuromyelitis optica: a systematic review. *Int J MS Care* 2013;15(3):113-8.

15. Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. *Arch Neurol* 2012;69(9):1176-80.

16. Houzen H, Kondo K, Niino M, Horiuchi K, Takahashi T, Nakashima I, et al. Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan. *Neurology* 2017;89(19):1995-2001.

17. Miyamoto K, Fujihara K, Kira J, Kuriyama N, Matsui M, Tamakoshi A, et al. The prevalence and characteristics of neuromyelitis optica in Japan: a nationwide epidemiological study. *J Neurol Sci* 2017;381:787.

18. Cabre P, Heinzel O, Merle H, Buisson GG, Bera O, Bellance R, et al. MS and neuromyelitis optica in Martinique (French West Indies). *Neurology* 2001;56(4):507-14.
19. Kim NH, Kim HJ, Cheong HK, Kim BJ, Lee KH, Kim EH, et al. Prevalence of multiple sclerosis in Korea. *Neurology* 2010;75(16):1432-8.
   [PUBMED](https://pubmed.ncbi.nlm.nih.gov/20813964/) [CROSSREF](https://doi.org/10.1212/WNL.0b013e3181f1a035)

20. Kim JE, Park SH, Han K, Kim HJ, Shin DW, Kim SM. Prevalence and incidence of neuromyelitis optica spectrum disorder and multiple sclerosis in Korea. *Mult Scler* 2019. DOI: 10.1177/1352458519888609.
   [PUBMED](https://pubmed.ncbi.nlm.nih.gov/30418734/) [CROSSREF](https://doi.org/10.1177/1352458519888609)

21. Langer-Gould A, Zhang JL, Chung J, Yeung Y, Waubant E, Yao J. Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children. *Neurology* 2011;77(12):1443-8.
   [PUBMED](https://pubmed.ncbi.nlm.nih.gov/21989974/) [CROSSREF](https://doi.org/10.1212/WNL.0b013e31822bcb8b)

22. Cho GJ, Park HT, Shin JH, Hur JY, Kim YT, Kim SH, et al. Age at menarche in a Korean population: secular trends and influencing factors. *Eur J Pediatr* 2010;169(1):89-94.
   [PUBMED](https://pubmed.ncbi.nlm.nih.gov/20141584/) [CROSSREF](https://doi.org/10.1007/s00431-009-1266-7)

23. Park CY, Lim JY, Park HY. Age at natural menopause in Koreans: secular trends and influences thereon. *Menopause* 2018;25(4):423-9.
   [PUBMED](https://pubmed.ncbi.nlm.nih.gov/29409260/) [CROSSREF](https://doi.org/10.1097/GCM.0000000000001112)

24. Kim SM, Waters P, Woodhall M, Kim YI, Kim JA, Cheon SY, et al. Gender effect on neuromyelitis optica spectrum disorder with aquaporin4-immunoglobulin G. *Mult Scler* 2017;23(8):1104-11.
   [PUBMED](https://pubmed.ncbi.nlm.nih.gov/28492060/) [CROSSREF](https://doi.org/10.1177/1352458517709857)

25. Lee MH, Kim SH, Oh M, Lee KW, Park MJ. Age at menarche in Korean adolescents: trends and influencing factors. *Reprod Health* 2016;13(1):121.
   [PUBMED](https://pubmed.ncbi.nlm.nih.gov/26528484/) [CROSSREF](https://doi.org/10.1186/s12978-016-0198-3)

26. Chen H, Qiu W, Zhang Q, Wang J, Shi Z, Liu J, et al. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder. *Eur J Neurol* 2017;24(1):219-26.
   [PUBMED](https://pubmed.ncbi.nlm.nih.gov/27865043/) [CROSSREF](https://doi.org/10.1111/ejn.13374)

27. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. *Neurology* 2015;85(2):177-89.
   [PUBMED](https://pubmed.ncbi.nlm.nih.gov/25611093/) [CROSSREF](https://doi.org/10.1212/WNL.0000000000001998)